Clinical improvement of some indicators of the activity of non-alcoholic fatty liver disease after correction of intestinal dysbiosis with dietary fiber

Relevance. Metabolic disorders in non-alcoholic fatty liver disease play a significant role in the development and progression of cardiovascular diseases, accelerating their occurrence, aggravating their course and outcomes. The occurrence and maintenance of a chronic staged course (from fatty hepatosis and non-alcoholic steatohepatitis to progressive liver fibrosis) of the disease is associated with quantitative and qualitative changes in the composition of the intestinal microflora. At the same time, outpatients may consider themselves healthy, which makes it difficult to implement a comprehensive treatment program. The peculiarities of the combination of clinical, laboratory and microbiological characteristics of patients with hepatic steatosis require detailed study for the earliest identification of therapeutic targets, diagnostic and prognostic tools and their effective correction. Purpose of the study: to determine the clinical, laboratory and microbiological characteristics of patients with non-alcoholic fatty liver disease. Material and methods: clinical, laboratory and microbiological data of outpatients were collected, anthropometric indicators were calculated. Statistical analysis: Microsoft Excel 2010 and StatTech v.3.1.8 (Russia) with assessment for normality of distribution and chi-square test. Differences were assessed by nonparametric analysis at a significance level of p<0.05. Results. Patients were assigned to the observation group if they had NAFLD or to the comparison group in it absence. Many patients in the observation group were found to have metabolic syndrome and/or abdominal obesity, accompanied by asthenic syndrome, functional disorders of the biliary tract, and disorders of lipid and carbohydrate metabolism. In the luminal microflora of the intestines of patients in the observation group, the presence of representatives of Pseudomonas spp. was significantly more often detected. Correction of microbiological disorders by adding dietary fiber to the diet provided clinical improvement. Conclusion. In addition to clinical and laboratory data, microbiological characteristics of patients can be used for the earliest diagnosis and effective correction of disorders that occur during the development of NAFLD.

nonalcoholic fatty liver disease (NAFLD), fatty hepatosis, outpatient care

1. Brea A., Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk.Int. J. Cardiol. 2013, 167(4): 1109-17. doi: 10.1016/j.ijcard.2012.09.085.

2. Boytsov S. A., Pogosova G. V., Bubnova M. G. et al. Cardiovascular prophylaxis 2017.Russian national guidelines.Russian Journal of Cardiology. 2018;23(6):7-122. (In Russ.) doi: 10.15829/1560-4071-2018-6-7-122.@@ Бойцов С. А., Погосова Г. В., Бубнова М. Г. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(23):7-122. doi: 10.15829/1560-4071-2018-6-7-122.

3. Oganov R. G., Maslennikova G. Ya. Individual prevention of cardiovascular diseases. The position of European cardiological societies. Cardiovascular therapy and prevention. 2017;16(1):4-7. (In Russ.) doi: 10.15829/1728-8800-2017-1-4-7.@@ Оганов Р. Г., Масленникова Г. Я. Индивидуальная профилактика сердечно-сосудистых заболеваний. Позиция европейских кардиологических обществ. Кардиоваскулярная терапия и профилактика. 2017;(16):4-7. doi: 10.15829/1728-8800-2017-1-4-7.

4. Nicoletti A., Ponziani F. R., Biolato M. et al.Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol. 2019;25(33):4814-34. doi: 10.3748/wjg.v25.i33.4814.

5. Ivashkin V. T., Drapkina O. M., Shulpekova Yu. O. Diagnosis and treatment of non-alcoholic fatty liver disease (Methodological recommendations). Moscow: Publishing House «M-Vesti» LLC, 2009. 20 p. (In Russ.)@@ Ивашкин В. Т., Драпкина О. М., Шульпекова Ю. О. Диагностика и лечение неалкогольной жировой болезни печени (Методические рекомендации). М.: ООО «Издательский дом «М-Вести», 2009. 20 с.

6. Drapkina O. M., Gatsolaeva D. S., Ivashkin V. T. Nonalcoholic fatty liver disease as a component of metabolic syndrome.Russian Medical News. 2010, 2: 72-8. (In Russ.)@@ Драпкина О. М., Гацолаева Д. С., Ивашкин В. Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома. Российские медицинские вести. 2010, 2: 72-8.

7. Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015, 239: 192-202. doi: 10.1016/j.атеросклероз.2015.01.001.

8. Sprecher D. L., Pearce G. L. How deadly is the “deadly quartet”? A post-CABG evaluation. J. Am. Coll. Cardiol. 2000 Oct;36(4):1159-65. doi: 10.1016/s0735-1097(00)00867-6.

9. Isomaa B., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001 Apr;24(4):683-9. doi: 10.2337/diacare.24.4.683.

10. Ametov A. S., Belykh A. A. Efficiency of correction of disorders of carbohydrate and lipid metabolism in persons with high risk factors.Russian Medical Journal. 2007, No. 28. pp. 2156-2160. (In Russ.)@@ Аметов А. С., Белых А. А. Эффективность коррекции нарушений углеводного и липидного обмена у лиц с высокими факторами риска. Русский медицинский журнал. 2007. № 28. С. 2156-2160.

11. Recommendations for the management of patients with metabolic syndrome. Clinical recommendations. Ministry of Health of the Russian Federation. 2013. 42 p. (In Russ.) Available at: http://medpoiskpro.ru/terapiya/klinicheskie-rekomendatsii-pokardiologii-2013. Accessed: 30 march 2023. @@ Рекомендации по ведению больных c метаболическим синдромом. Клинические рекомендации. Министерство здравоохранения РФ. 2013. 42 с. URL: http://medpoiskpro.ru/terapiya/klinicheskie-rekomendatsii-pokardiologii-2013.

12. Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obesepatients undergoing bariatric surgery. J. Hepatol. 2016, 45(4):600-6. doi: 10.1016/j.jhep.2006.06.013.

13. Gaggini M., Morelli M., Buzzigoli E., DeFronzo R. A., Bugianesi E., Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013, 5(5): 1544-60. doi: 10.3390/nu5051544.

14. Chang E., Park C. Y., Park S. W. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J. Diabetes Investig. 2013, 4(6): 517-24. doi: 10.1111/jdi.12107.

15. Williamson R. M., Price J. F., Glancy S., Perry E., Nee L. D., Hayes P. C. et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes Study. Diabetes Care. 2011; 34(5): 1139-44. doi: 10.2337/dc10-2229.

16. Trukhan D. I., Filimonov S. N. Clinic, diagnosis and treatment of major endocrine and hematological diseases. Novokuznetsk: OOO “Polygraphist”, 2015. 119 p. (In Russ.)@@ Трухан Д. И., Филимонов С. Н. Клиника, диагностика и лечение основных эндокринных и гематологических заболеваний. Новокузнецк: ООО «Полиграфист», 2015. 119 с.

17. Trukhan D. I. Nonalcoholic fatty liver disease associated with obesity: the possibilities of essential phospholipids. Medical advice. Gastroenterology. 2016, 4: 116-122. (In Russ.) doi: 10.21518/2079-701X-2016-9-64-69.@@ Трухан Д. И. Неалкогольная жировая болезнь печени, ассоциированная с ожирением: возможности эссенциальных фосфолипидов. Медицинский совет. Гастроэнтерология. 2016, 4: 116-122. doi: 10.21518/2079-701X-2016-9-64-69.

18. Ulluwishewa D., Anderson R., McNabb W. Regulashion of tight junction permeability by intestinal bacteria and Dietary components. J Nutr. 2011; 141(5):769-76. doi: 10.3945/jn.110.135657.

19. Zou Y., Lin X., Xue W. et al. Characterization and description of Faecalibacterium butyricigenerans sp. nov. and F. longum sp. nov., isolated from human faeces. Sci Rep. 2021;11:11340. doi: 10.1038/s41598-021-90786-3.

20. Buffie C. G., Bucci V., Stein R. R. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205-8. doi: 10.1038/ nature13828.

21. Assimakopoulos S. F., Triantos C., Maroulis I., Gogos C. The Role of the Gut Barrier Function in Health and Disease. Gastroenterology Res. 2018;11(4):261-3. doi: 10.14740/gr1053w.

22. Alvarez J. et al. Gut microbes and health. Gastroenterol Hepatol. 2021; 44(7):519-535. doi: 10.1016/j.gastre.2021.01.002.

23. Bloomgarden Z. T. Symposium: Debating the Metabolic Syndrome. Medscape Conference Coverage, based on selected sessions. American Diabetes Association 66th Scientific Sessions; June 9-13, 2006, Washington, DC.

24. Shergill R., Syed W., Rizvi S.A, Singh I. Nutritional support in chronic liver disease and cirrhotics. World J Hepatol. 2018 Oct 27;10(10):685-694. doi: 10.4254/ wjh.v10.i1 0.685.

25. European Association for the Study of the Liver. Electronic address: easloffi ce@easloffi ce.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liv er disease. J Hepatol. 2019 Jan;70(1):172-193. doi: 10.1016/j. jhep.2018.06.024.

26. Henkel A. S., Buchman A. L. Nutritional su pport in patients with chronic liver disease. Nat Clin Pract Gastroenterol Hepatol. 2006 Apr;3(4):202-9. doi: 10.1038/ncpgasthep0443.

27. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231. doi: 10.1056/NEJMra011775 2.

28. Chen P., Torralba M., Tan J. et al. Supplementation of saturated l ong-chain fatty acids maintains intestinal eubiosis and reduces ethanol- induced liver injury in mice. Gastroenterology. 2015 Jan;148(1):203-214.e16. doi: 10.1053/j.gastro.2014.09.014.

29. Pace A., de Weerth A., Berna M. et al. Pancreas and liver injury are associated in individuals with incr eased alcohol consumption. Clin. Gastroenterol. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1241-6. doi: 10.1016/j.cgh.2009.06.010.